Print

Purpose

An open label study to investigate the safety and efficacy of ponesimod in participants with moderate-to-severe chronic plaque psoriasis

Condition

Eligibility

Eligible Ages
Between 18 Years and 65 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Male and female subjects aged 18-65 years, inclusive - BMI >18 and <40 - Minimum affected BSA of 10% - PASI score ≥ 12 - PGA ≥ 3 - Diagnosed with moderate-to-severe plaque psoriasis

Exclusion Criteria

  • Diagnosis of generalized erythrodermic, generalized pustular (von Zumbusch), guttate, or palmoplantar psoriasis - History of an allergic reaction or known and/or significant sensitivity to study drug

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Ponesimod 		Ponesimod
  • Drug: Ponesimod
    Oral Tablet

Recruiting Locations

Vanda Investigational Site
Glendale, Arizona 85308

Vanda Investigational Site
Fremont, California 94538

Vanda Investigational Site
Rochester, New York 14623

Vanda Investigational Site
Spokane, Washington 99202

More Details

Status
Recruiting
Sponsor
Vanda Pharmaceuticals

Study Contact

Vanda Pharmaceuticals, Inc.
202-734-3400
clinicaltrials@vandapharma.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.